Halozyme Therapeutics
HALO
Lantheus
LNTH
Constellation Brands
STZ
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
Collegium Pharmaceutical
COLL
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -18.11%1.17B | -20.11%282.8M | -23.50%296.9M | -14.60%258M | -13.62%335.6M | 52.25%1.43B | 17.26%354M | 50.48%388.1M | 99.80%302.1M | 68.91%388.5M |
Net income from continuing operations | -0.38%1.15B | -1.61%262.1M | 0.88%298.1M | -1.78%292.7M | 0.88%297.7M | 6.27%1.16B | 8.47%266.4M | 3.83%295.5M | 3.80%298M | 9.46%295.1M |
Operating gains losses | 11.63%-3.8M | 50.00%-800K | 13.33%-1.3M | -83.33%-1.1M | 0.00%-600K | -490.91%-4.3M | -1,500.00%-1.6M | -36.36%-1.5M | 50.00%-600K | -117.14%-600K |
Depreciation and amortization | -1.07%175.4M | 2.78%44.4M | -0.67%44.4M | -2.67%43.7M | -3.60%42.9M | 0.40%177.3M | -3.36%43.2M | 1.36%44.7M | 2.28%44.9M | 1.37%44.5M |
Deferred tax | 61.68%-4.1M | -9.52%-6.9M | 132.00%1.6M | 33.33%400K | 166.67%800K | -118.37%-10.7M | 31.52%-6.3M | -231.58%-5M | 160.00%300K | -70.00%300K |
Change In working capital | -245.51%-154.1M | -139.16%-19.5M | -193.97%-48.3M | -81.82%-80M | -112.94%-6.3M | 132.68%105.9M | 162.11%49.8M | 169.84%51.4M | 75.60%-44M | 154.60%48.7M |
-Change in receivables | 55.88%-31.9M | -6.42%81.6M | 264.44%7.4M | 131.46%6.7M | 4.56%-127.6M | 39.65%-72.3M | -15.42%87.2M | 66.91%-4.5M | 45.94%-21.3M | 21.31%-133.7M |
-Change in inventory | -170.81%-133.9M | -3,657.69%-97.7M | -204.99%-48.4M | -111.04%-9.7M | -62.05%21.9M | 195.51%189.1M | 87.68%-2.6M | 275.29%46.1M | 218.46%87.9M | 175.52%57.7M |
-Change in payables and accrued expense | 41.03%11M | -57.61%-14.5M | -5.98%17.3M | 1,125.00%24.5M | -379.41%-16.3M | 122.10%7.8M | 85.51%-9.2M | 2,144.44%18.4M | -16.67%2M | -112.73%-3.4M |
-Change in other current assets | -85.94%-11.9M | 135.32%7.7M | -214.46%-26.1M | -30.88%-28.4M | -23.13%34.9M | -128.19%-6.4M | -420.59%-21.8M | 80.70%-8.3M | -1,105.56%-21.7M | -25.21%45.4M |
-Change in other working capital | 202.44%12.6M | 189.47%3.4M | 600.00%1.5M | 19.58%-73.1M | -2.30%80.8M | -295.24%-12.3M | 39.68%-3.8M | -102.94%-300K | -35.07%-90.9M | 18.65%82.7M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -18.11%1.17B | -20.11%282.8M | -23.50%296.9M | -14.60%258M | -13.62%335.6M | 52.25%1.43B | 17.26%354M | 50.48%388.1M | 99.80%302.1M | 68.91%388.5M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -33.06%-214.5M | -74.24%-57.5M | -30.00%-55.9M | 2.77%-52.7M | -56.13%-48.4M | 1.10%-161.2M | 20.29%-33M | 3.37%-43M | -23.46%-54.2M | 6.63%-31M |
Net PPE purchase and sale | -33.31%-214.1M | -74.47%-57.4M | -30.07%-55.8M | 2.41%-52.6M | -56.31%-48.3M | 1.11%-160.6M | 20.72%-32.9M | 3.38%-42.9M | -24.19%-53.9M | 6.65%-30.9M |
Net other investing changes | 33.33%-400K | 0.00%-100K | 0.00%-100K | 66.67%-100K | 0.00%-100K | 0.00%-600K | -200.00%-100K | 0.00%-100K | 40.00%-300K | 0.00%-100K |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -33.06%-214.5M | -74.24%-57.5M | -30.00%-55.9M | 2.77%-52.7M | -56.13%-48.4M | 1.10%-161.2M | 20.29%-33M | 3.37%-43M | -23.46%-54.2M | 6.63%-31M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 28.71%-913.7M | 37.88%-250.1M | 26.56%-210.7M | 23.76%-185.5M | 23.36%-267.4M | -65.40%-1.28B | -49.83%-402.6M | -29.94%-286.9M | -183.24%-243.3M | -74.89%-348.9M |
Net issuance payments of debt | 79.66%-60M | ---40M | 105.56%5M | 170.00%35M | 61.29%-60M | -278.79%-295M | --0 | -280.00%-90M | -135.71%-50M | -520.00%-155M |
Net common stock issuance | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Cash dividends paid | 12.15%-893.3M | 46.47%-223.4M | -11.81%-223.4M | -11.71%-223.3M | -11.71%-223.2M | -42.95%-1.02B | -135.90%-417.3M | -12.56%-199.8M | -11.99%-199.9M | -12.00%-199.8M |
Proceeds from stock option exercised by employees | 31.56%39.6M | -9.52%13.3M | 165.52%7.7M | -57.58%2.8M | 167.80%15.8M | 227.17%30.1M | 950.00%14.7M | 45.00%2.9M | 247.37%6.6M | 51.28%5.9M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 28.71%-913.7M | 37.88%-250.1M | 26.56%-210.7M | 23.76%-185.5M | 23.36%-267.4M | -65.40%-1.28B | -49.83%-402.6M | -29.94%-286.9M | -183.24%-243.3M | -74.89%-348.9M |
Net cash flow | ||||||||||
Beginning cash position | -3.82%221.3M | -1.78%292.2M | 4.89%255.5M | -1.13%237.1M | -3.82%221.3M | -2.58%230.1M | 28.51%297.5M | -1.73%243.6M | 2.39%239.8M | -2.58%230.1M |
Current changes in cash | 542.16%45.1M | 69.61%-24.8M | -47.94%30.3M | 330.43%19.8M | 130.23%19.8M | -429.03%-10.2M | -895.12%-81.6M | 886.49%58.2M | -78.50%4.6M | 418.52%8.6M |
Effect of exchange rate changes | -857.14%-10.6M | -314.81%-11.6M | 248.84%6.4M | -75.00%-1.4M | -463.64%-4M | 115.22%1.4M | -20.59%5.4M | 52.22%-4.3M | 89.61%-800K | 57.14%1.1M |
End cash Position | 15.59%255.8M | 15.59%255.8M | -1.78%292.2M | 4.89%255.5M | -1.13%237.1M | -3.82%221.3M | -3.82%221.3M | 28.51%297.5M | -1.73%243.6M | 2.39%239.8M |
Free cash flow | -24.85%946.8M | -29.93%222.6M | -30.39%237.5M | -17.99%201.9M | -19.73%284.8M | 64.22%1.26B | 22.62%317.7M | 62.55%341.2M | 137.42%246.2M | 82.42%354.8M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |